These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25862616)

  • 1. Belimumab and the measurement of fatigue.
    Mazzoni D
    Ann Rheum Dis; 2015 Sep; 74(9):e53. PubMed ID: 25862616
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: 'belimumab and the measurement of fatigue' by Mazzoni.
    Strand V; Levy RA; Cervera R; Petri M
    Ann Rheum Dis; 2015 Sep; 74(9):e54. PubMed ID: 25990291
    [No Abstract]   [Full Text] [Related]  

  • 3. Belimumab in systemic lupus erythematosus -- what can be learned from longterm observational studies?
    Bengtsson AA
    J Rheumatol; 2014 Feb; 41(2):192-3. PubMed ID: 24488851
    [No Abstract]   [Full Text] [Related]  

  • 4. [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):66-7. PubMed ID: 23565550
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus.
    Kumthekar A; Danve A; Deodhar A
    J Rheumatol; 2017 Sep; 44(9):1416-1417. PubMed ID: 28864669
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
    Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
    Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Belimumab--the biological drug for systemic lupus erythematosus: as discussed during the American College of Rheumatology (ACR) conference - 2012].
    Vadasz Z; Toubi E
    Harefuah; 2013 May; 152(5):304-6. PubMed ID: 23885457
    [No Abstract]   [Full Text] [Related]  

  • 8. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.
    Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
    Ann Rheum Dis; 2019 Jul; 78(7):1006-1007. PubMed ID: 30610063
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus.
    De Marchi G; Quartuccio L; Bond M; De Vita S
    Clin Exp Rheumatol; 2017; 35(6):1056. PubMed ID: 28770706
    [No Abstract]   [Full Text] [Related]  

  • 10. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab.
    Hara M; Ogawa-Momohara M; Muro Y; Takeichi T; Akiyama M
    Eur J Dermatol; 2020 Oct; 30(5):615-617. PubMed ID: 32972910
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab.
    Sciascia S; Rubini E; Radin M; Cecchi I; Rossi D; Roccatello D
    Ann Rheum Dis; 2018 Nov; 77(11):1694-1695. PubMed ID: 29776976
    [No Abstract]   [Full Text] [Related]  

  • 13. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.
    Husein-ElAhmed H; Callejas-Rubio JL; Rios-Fernandez R; Ortego-Centeno N
    Indian J Dermatol Venereol Leprol; 2014; 80(5):477-8. PubMed ID: 25201862
    [No Abstract]   [Full Text] [Related]  

  • 14. Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital.
    Riancho-Zarrabeitia L; Villa Blanco I; Santos-Gómez M; Aurrecoechea E
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):188-189. PubMed ID: 29555189
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
    Nagel J; Saxne T; Geborek P; Bengtsson AA; Jacobsen S; Svaerke Joergensen C; Nilsson JÅ; Skattum L; Jönsen A; Kapetanovic MC
    Lupus; 2017 Sep; 26(10):1072-1081. PubMed ID: 28420056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity.
    Sjöwall C; Cöster L
    Scand J Rheumatol; 2014; 43(5):428-30. PubMed ID: 24689946
    [No Abstract]   [Full Text] [Related]  

  • 17. When to use belimumab in SLE.
    Gatto M; Iaccarino L; Zen M; Doria A
    Expert Rev Clin Immunol; 2017 Aug; 13(8):737-740. PubMed ID: 28463023
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.